Ann: Anteris Completes DurAVR THV EFS Enrolment, page-9

I think this is where we need to have patience as long-term investors. We know the company, like all clinical stage companies, is hungry for cash and that the options in the last raise provided for a second infusion of money if the market had cooperated, but it didn't. Unfortunately there's no magic wand any of us or anybody at the company can waive to get the share price above $29 so we are where we are and need another raise that will most likely include sweeteners for those who pony up the big bucks.

We have seen nice progress recently by the company with the EFS completion now being imminent and the launch of a new US ticker, so the company is executing well but we're still in the relatively early stages of a long game.